Invech Holdings, Inc. Files Amendment 3 to S-1 Registration Statement

TL;DR

<b>Invech Holdings, Inc. has filed an S-1/A Amendment 3, updating its registration statement under the Securities Act of 1933.</b>

AI Summary

Invech Holdings, Inc. (IVHI) filed a Amended IPO Registration (S-1/A) with the SEC on April 9, 2024. Invech Holdings, Inc. filed an S-1/A Amendment 3 on April 9, 2024. The filing pertains to a registration statement under the Securities Act of 1933. The company was formerly known as Amersin Life Sciences CORP, HUBEI PHARMACEUTICAL GROUP LTD, and PAN ASIA COMMUNICATIONS CORP. The principal executive offices are located at 7339 E. Williams Drive Unit 26496, Scottsdale, AZ 85255. The agent for service is Pacific Stock Transfer Co. located in Las Vegas, NV.

Why It Matters

For investors and stakeholders tracking Invech Holdings, Inc., this filing contains several important signals. This amendment indicates ongoing efforts by Invech Holdings to register securities, suggesting potential future public offerings or stock-related activities. The company's history of name changes (Amersin Life Sciences CORP, HUBEI PHARMACEUTICAL GROUP LTD, PAN ASIA COMMUNICATIONS CORP) may indicate significant corporate restructuring or strategic shifts over time.

Risk Assessment

Risk Level: low — Invech Holdings, Inc. shows low risk based on this filing. The filing is an S-1/A amendment, which is a routine update to a registration statement and does not contain new financial performance data or significant business developments.

Analyst Insight

Monitor future filings for updates on the proposed sale of securities and any disclosed business strategies.

Key Numbers

• 333-276779 — SEC File Number (Registration statement file number)
• 2024-04-09 — Filing Date (Date of S-1/A Amendment 3 filing)
• 1933 — Securities Act (Act under which registration statement is filed)
• 880419476 — IRS Number (Registrant's IRS Employer Identification No.)

Key Players & Entities

• Invech Holdings, Inc. (company) — Registrant name
• Amersin Life Sciences CORP (company) — Former company name
• HUBEI PHARMACEUTICAL GROUP LTD (company) — Former company name
• PAN ASIA COMMUNICATIONS CORP (company) — Former company name
• Pacific Stock Transfer Co. (company) — Agent for service
• Rhonda Keaveney (person) — Correspondence contact
• Scottsdale, AZ (location) — Principal executive offices address
• Las Vegas, NV (location) — Agent for service address

FAQ

Industry Context

The filing is related to the registration of securities under the Securities Act of 1933, a standard process for companies intending to offer securities to the public.

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the initial offering and sale of securities in the United States.

What Investors Should Do

1. Review future SEC filings from Invech Holdings for updates on the registration statement.
2. Investigate the company's business activities and strategic direction given its history of name changes.
3. Track any announcements regarding the proposed sale of securities mentioned in the filing.

Year-Over-Year Comparison

This is an amendment (Amendment 3) to a previously filed registration statement, indicating ongoing regulatory processes rather than a new filing.

Key Financial Figures

• $25,000 — n of operations we require a minimum of $25,000 to maintain websites, email campaigns,
• $2,083 — Our monthly burn rate is approximately $2,083. The month on which we will run out of
• $0 — 022, the Company incurred a net loss of $0 and used cash of $0 for operating activ
• $176,558 — cit of $0 and an accumulated deficit of $176,558. These factors raise substantial doubt
• $30,641 — mber 31, 2023, SCC advanced the Company $30,641 to pay for general operating expenses.

Filing Documents

• invech_s1a3.htm (S-1/A) — 679KB
• 0001683168-24-002217.txt (&nbsp;) — 680KB

RISK FACTORS

RISK FACTORS 6 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 15 DIVIDEND POLICY 15 MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS 16

USE OF PROCEEDS

USE OF PROCEEDS 16 DETERMINATION OF OFFERING PRICE 16

DILUTION

DILUTION 16 SELLING SECURITY HOLDERS 17 PLAN OF DISTRIBUTION-SELLING STOCKHOLDERS 22

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 25 LEGAL MATTERS 27 EXPERTS 27 INTERESTS OF NAMED EXPERTS AND COUNSEL 27 MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 28 DESCRIPTION OF BUSINESS 34 MARKET FOR OUR COMMON STOCK 39 DIRECTORS AND EXECUTIVE OFFICERS 40

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 46 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS 47

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 49 DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES 50 WHERE YOU CAN FIND MORE INFORMATION 53 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS F-1 i ABOUT THIS PROSPECTUS You should rely only on the information contained in this prospectus or contained in any prospectus supplement or free writing prospectus filed with the Securities and Exchange Commission (the &ldquo; SEC &rdquo;). Neither we nor the selling stockholders have authorized anyone to provide you with additional information or information different from that contained in this prospectus filed with the SEC. The selling stockholders are offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions where offers and sales are permitted. The information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside the United States: Neither we nor the selling stockholders have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside the United States. As used in this prospectus, unless otherwise designated, the terms &ldquo; we ,&rdquo; &ldquo; us ,&rdquo; &ldquo; our ,&rdquo; the &ldquo; Company ,&rdquo; &ldquo; IVHI &rdquo; and &ldquo; our Company &rdquo; refer to Invech Holdings, Inc., a Nevada corporation. ii CAUTION REGARDING FORWARD-LOOKING STATEMENTS

SUMMARY INFORMATION, RISK FACTORS AND RATIO OF EARNINGS TO FIXED CHARGES

ITEM 3. SUMMARY INFORMATION, RISK FACTORS AND RATIO OF EARNINGS TO FIXED CHARGES We and our business are subject to material risks, which could cause actual results, performance and achievements to differ materially from those anticipated, and the risk factors set forth in the section entitled &ldquo; Risk Factors &rdquo; beginning on page 6 of this prospectus. These risks can be summarized as follows: Business Related Risks &middot; We have incurred operating losses in some of our historical periods and we could incur additional losses until we successfully integrate acquired practices, improve collections for procedures and reduce operating expenses. &middot; Our capital resources may not be sufficient to meet our capital requirements, and in the absence of additional resources we may have to curtail or cease business operations. &middot; We may encounter substantial competition in the public company compliance consulting industry and our failure to compete effectively may adversely affect our ability to generate revenue. &middot; We may face a number of risks associated with our business services, including the possibility that we may incur substantial debt or convertible debt, which could adversely affect our financial condition. &middot; Our development will depend on the efforts of key management, key personnel and our relationships with operators and other partnerships. &middot; Our officers, directors and principal stockholders own a large percentage of our stock and other stockholders have little or no ability to elect directors or influence corporate matters. Risk Related to our Stock &middot; Our stock trades on an unsolicited basis only, so you may be unable to sell your shares at or near the quoted bid prices if you need to sell a significant number of your shares. &middot; Our common stock is defined as &ldquo;penny stock&rdquo; under the Exchange Act, and the rules promulgated thereunder. &middot; We may issue more shares in an

View Full Filing

View this S-1/A filing on SEC EDGAR